1. Based on the data, only one of the four treatments that were analyzed, Capomulin, resulted in tumor shrinkage at the end of the 45-day treatment. The other three treatments resulted in greater than 40% increases in tumor size.
2. The Capomulin treatment also performed better than the other treatments when it came to the mice survival rate (higher than the other treatments) and the change in metastatic sites (slower rate than the other treatments).
3. The Infubinol and Ketapril treatments performed essentially on par with the Placebo treatment if not worse in some aspects. Based on these trial results, it would be accurate to conclude that these treatments should not be continued due to lack of a positive response.